

HAE On the Horizon



Uniting a Community and
Looking Toward a Brighter Future



Look for *HAE On the Horizon*

We have learned, through continuous communications and engagement with our community, that far too many HAE friends, for one reason or another, may not have the full range of knowledge to adequately control their HAE.

With this in mind, the US HAEA is launching our ***HAE On the Horizon***, a quarterly update containing vital information about current therapies, opportunities to participate in clinical trials and other research pursuing treatment options, and the latest scientific breakthroughs. The newsletter will also announce the dates and times for exclusive US HAEA educational webinars featuring renowned experts who will discuss the latest on important issues facing our patient community and answer your questions.

We hope that this resource will help you and your physician assess your current HAE management plan and make any necessary improvements.

Available HAE treatments serve as the corner stone for successful management of HAE symptoms. Please visit the websites provided below for detailed information about: how each therapy works and is administered. Information regarding side effects and safety are also offered.

Did you know?

There are currently 6 products approved by the FDA for preventing and treating HAE attacks:
(Listed in order of FDA approval dates)

CINRYZE® is an FDA-approved C1-inhibitor concentrate for preventing HAE attacks in teenagers and adults. Cinryze™ is delivered intravenously and is approved for home infusion to prevent HAE attacks. For more information visit:
www.cinryze.com

BERINERT® is an FDA-approved C1-inhibitor concentrate for treating acute HAE attacks in adults and pediatric patients. Berinert® is delivered intravenously and is approved for on-demand treatment through self-administration. For more information visit:
www.berinert.com

KALBITOR® is an FDA-approved kallikrein inhibitor for treating acute HAE attacks in patients 12 years of age and older. Kalbitor® is delivered by subcutaneous injection and must be administered by a healthcare professional. For more information visit:
www.kalbitor.com

FIRAZYR® is an FDA-approved B2 bradykinin receptor antagonist for treating acute HAE attacks in patients 18 years and older. Firazyr® is delivered by subcutaneous injection and is approved for self-administration. For more information visit:
www.firazyr.com

RUCONEST® is an FDA-approved plasma free recombinant C1-inhibitor concentrate for treating acute HAE attacks in adults and adolescents. Ruconest® is delivered intravenously and is approved for self-administration. For more information visit:
<https://www.ruconest.com>

HAEGARDA® is a self-administered, plasma-derived concentrate of C1 INH and the only subcutaneous therapy approved for routine prophylaxis to prevent HAE attacks in adolescent and adult patients. For more information, visit: www.haegarda.com

Consult your doctor to determine which therapy is best for you.

See the latest news on HAE therapies:

RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema

https://www.haea.org/ci/page/show/press/8/shire_phase3

Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial

https://www.haea.org/ci/page/show/press/8/shire_phase3

FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease

<http://www.cslbehring.com/newsroom/fda-approves-HAEGARDA-for-hereditary-angiodema>

Positive Clinical Trial Results cited for Shire's Lanadelumab subcutaneous long acting prophylactic kalikrein Inhibitor

<https://www.shire.com/en/newsroom/2017/may/uftdvv>

Pharming announces publication of RUCONEST® prophylactic data in The Lancet

<https://www.pharming.com/pharming-announces-publication-of-ruconest-prophylactic-data-in-the-lancet/>

Positive Clinical Trial results cited for CSL Behring's Haegarda subcutaneous C1 Inhibitor Prophylactic Therapy

<http://www.cslbehring.com/newsroom/NEJM-publishes-data-on-preventing-HAE-attacks.htm?tabSelections=1255923338674¤tPage=1>

BioCryst reports encouraging results in Phase 2 APeX-1 trial of hereditary angioedema treatment

<http://patientdaily.com/stories/511102881-biocryst-reports-encouraging-results-in-phase-2-apex-1-trial-of-hereditary-angioedema-treatment>

Erienne Leatherman

BioCryst Expands Development of BCX7353 to Explore an Oral Treatment for Acute Acute HAE Attacks

<http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=1021056>

